semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Persistent Asthma at least 12 years of age diagnosis of asthma and no current or previous history of smoking  exacerbation of asthma or hospitalization for asthma within 8 weeks prior to enrollment predominant COPD and bronchiectasis by clinical and/or radiological assessment history of cough syncope pregnant or nursing women not fluent in English inability to comply with study procedures
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 1.0-17.0,  Asthma Subject will be eligible if he/she: 1. is aged 1 to 17 years, 2. has not received any oral, IM or IV corticosteroid within the last 5 days? 3. Presents to the hospital emergency department with an acute episode of cough, wheezing and/or dyspnea? 4. Has asthma as defined as one or more of the following 6 (i) prior diagnosis of asthma made by a physician; OR (ii) prior documented episode of acute cough, wheezing and/or dyspnea with significant response to inhaled β2-agonists or to oral corticosteroids; OR (iii) in a child aged <2 years, 3 or more episodes of cough, wheezing and/or dyspnea, including the index visit; OR (iv) previous lung function tests showing significant reversibility post-bronchodilation (≥12% FEV1 or ≥25% Rrs at 4 to 8 Hz); OR (v) a positive provocation test (PC20 ≤8 mg/mL or Provocation Dose (to increase Rrs by 50% or more (PD50) ≤8 mg/mL), OR (vi) the current episode diagnosed or suspected of asthma by the emergency physician? 5. have moderate or severe airway obstruction, defined as a Paediatric Respiratory Asthma Measure (PRAM) score >3 at baseline  Patient will be excluded if : 1. he/she has another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic fibrosis); 2. there is a reasonable suspicion of bronchiolitis or foreign body aspiration; 3. he/she has a prior history of hypersensitivity to salbutamol, ipratropium bromide or oral prednisone/prednisolone; 4. he/she has a relative or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine in past 14 days, 5. there is confirmed or suspected pregnancy
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 60.0-70.0,  Subjective Discomfort General Mucosal Irritation Acute Changes in Respiratory Outcomes Acute Changes in Cardiovascular Outcomes Changes in Biomarkers Non-smoker Normal lung function No active allergic rhinitis Be free from clinically significant cardiac, pulmonary, neurological and psychiatric disease as determined by medical history, physical examination and screening investigations With no clinically-significant deviation outside the normal ranges for blood presure and pulse Measurements Capable of giving informed consent Be avaible to complete the study Provide oral and written informed consent to participate in the study  Atopy Upper respiratory tract infection within 2 weeks Medical conditions likely to affect the outcome of the study in the opion of the investigator Presence of any respiratory disease Infection of the upper Airways/lower Airways includingviral infections in the 14 days prior to screening and at the start of/or during the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 19.0-85.0,  Asthma Mixed Asthma With Acute Exacerbation Physician diagnosed asthma. 2. A history of an asthma exacerbation requiring oral corticosteroids or admission to Emergency Department/hospital in the previous year. 3. Ability to understand English and follow the material included in the two different interventions. 4. Ownership of a mobile phone with the capacity to support text messaging. 5. Patients on maintenance inhaled corticosteroids alone or with a combination inhaler. Subjects on other controller therapies will not be excluded as long as they fulfill these criteria. -  Inability to provide written informed consent. 2. A history of smoking cigarettes for greater than ten pack years. 3. Not owning a mobile cell phone. 4. Subjects only taking a reliever medication and on no controller medication. 5. A history of significant co morbid disease judged by the investigator to preclude enrolment. 6. A history of an asthma exacerbation requiring oral corticosteroids in the previous six weeks. 7. Plans to move out of the study area in the next year. -
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Eighteen-year-old or older Patients whose asthma is not controlled with more than three months of using high dose inhaled steroids and long acting β2-agonists Patients with pre-bronchodilator FEV1 is between sixty and eighty-five% Patients who do not improve through continuous drug uses  Presence of a pacemaker, internal defibrillator, or other implantable electronic devices Known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, and benzodiazepines Patients previously treated with the Alair System should not be retreated in the same area(s). No clinical data are available studying the safety and/or effectiveness of repeat treatments Active respiratory infection Asthma exacerbation or changing dose of systemic corticosteroids for asthma (up or down) in the past 14 days Known coagulopathy As with other bronchoscopic procedures, patients should stop taking anticoagulants, antiplatelet agents, aspirin and before the procedure with physician guidance
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Severe Asthma Children 0-18 years patients followed regularly for at least one year The diagnosis of asthma is increased according to the of the Global Initiative for Asthma (GINA): children with a history of recurrent episodes of bronchial obstruction children with severe asthma defined by the American Thoracic Society (ATS): Severe asthma is defined by the presence of a major criterion: the need for high doses of inhaled corticosteroids (budesonide dose equivalent 400 micro g) and least two of the five minor The daily use of beta 2 long-acting or short-term daily action (<4 years) or anti-leukotrienes associated with inhaled corticosteroids Daily or almost daily use of beta-2 short-acting Permanent-bronchial obstruction (FEV <80% predicted FEV) At least one emergency department visit for asthma exacerbations in France At least 3 courses of oral corticosteroids per year  parents' refusal to participate in the study refusal children to participate pathology underlying cardiac, neuromuscular, immunodeficiency
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Asthma Age ranging between 18 and 45 years Diagnosis of asthma No exacerbations during last month  History of spine surgery Diabetes, neurological or a cardiovascular disease Spine deformities and use of orthopedic devices
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-11.0,  Asthma Physician-diagnosed asthma At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in the past 12 months Able to perform reproducible spirometry Current treatment with step 2 controller therapy [low-dose ICS, leukotriene receptor antagonist (LTRA)] OR current treatment with step 3 controller therapy [low-dose ICS + long-acting beta agonist (LABA), low-dose ICS + LTRA, or medium dose ICS] with a childhood Asthma Control Test (c-ACT) score of >19, no more than 2 prednisone treated exacerbations in the past 6 months, prebronchodilator Forced Expiratory Volume at 1 second (FEV1) ≥ 80% predicted and willing to step down therapy OR controller naïve and qualifying for step 2 controller therapy [asthma symptoms or short acting beta agonist (SABA) use > 2 days per week or night-time awakenings due to asthma > 2 nights per month] Prebronchodilator FEV1 ≥ 60% predicted Ability and willingness to provide informed assent For females of childbearing potential: not pregnant, non-lactating, and agree to practice an adequate birth control method History of clinical varicella or varicella vaccine  Systemic (oral or injectable) corticosteroids within previous 2-week period Current or recent (previous 2-weeks) use of medications known to significantly interact with corticosteroid disposition, including but not limited to carbamazepine, erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole Presence of chronic or active lung disease other than asthma Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study A history of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure More than 5 prednisone treated exacerbations in the past 12 months More than 1 hospitalizations lasting >24 hours for asthma in the past 12 months History of adverse reactions to ICS preparations or any of their ingredients Receiving hyposensitization therapy other than an established maintenance regimen (On maintenance regimen for ≥ 3 months)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Physician-diagnosed asthma for at least previous 12 months Able to perform reproducible spirometry Baseline FEV1≥70% of predicted Asthma confirmed either by Beta-agonist reversibility to 4 puffs albuterol ≥ 12% OR Methacholine PC20 ≤ 16 mg/ml At least 1 of the following indications for chronic controller therapy Asthma Symptoms > 2 days/week OR Nocturnal Asthma Symptoms > 2 nights/month OR Short-acting beta-agonist use for symptom control > 2 days/week  Chronic inhaled or oral corticosteroid therapy Use of inhaled or oral corticosteroid therapy within 6 weeks New allergen immunotherapy within the past 3 months or anticipated changes to an ongoing immunotherapy regimen Use of omalizumab within 3 months History of bladder-neck obstruction, urinary retention or benign prostatic hyperplasia narrow angle glaucoma significant cardiovascular disorders and arrhythmias life-threatening asthma requiring treatment with intubation or mechanical ventilation within the past 5 years Respiratory tract infection within past 6 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Severe Hemophilia A Key Have severe hemophilia A Previously treated subject, defined as having at least 150 documented prior exposure days to any recombinant and/or plasma-derived FVIII and/or cryoprecipitate products (other than any use of rFVIIIFc study drug or commercial product) at Day 1. Fresh frozen plasma treatment must not be considered in the count for documented exposure days No history of a positive inhibitor test or clinical signs of decreased response to FVIII administrations. Family history of inhibitors will not subjects No measurable inhibitor activity using the Nijmegen-modified Bethesda assay at Screening Platelet count ≥100,000 platelets/μL at screening CD4 lymphocytes >200 mm3 if known as HIV antibody positive at screening Viral load of <400 copies/mL if known HIV antibody positive at screening. Key  Subject is at high risk of bleeding during the 5-day period between the first and second injections for PK analyses, as per Investigator discretion Previous treatment with rFVIIIFc as study drug or commercial product Other coagulation disorder(s) in addition to hemophilia A History of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration Currently taking (or likely to require during the study) acetylsalicylic acid (ASA), except for low-dose ASA as prophylaxis (other nonsteroidal anti-inflammatory drugs are permitted) Concurrent systemic treatment with immunosuppressive drugs within 12 weeks prior to Day 1. Exceptions to this ribavirin for treatment of hepatitis C virus (HCV), and/or systemic steroids (a total of 2 courses of pulse treatments lasting no more than 7 days at a dose of ≤1 mg/kg within 12 weeks prior to Day 1) and/or inhaled steroids. NOTE: Other protocol-defined inclusion/ May Apply
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Asthma Age ≥ 12 and ≤ 17 years Access to Apple or Android based smart phone Mild to severe persistent asthma or poorly controlled asthma (see definitions below). o A different assessment of will be performed depending on whether or not the parent reports use of a preventive asthma medication at baseline. This is consistent with 2007 National Asthma Education Prevention Program recommendations that make a strong distinction between classifying asthma severity (for children not using preventive medications) and assessing control (for children using preventive medications). If a child has used a preventive medication in the past, but reports no use of the medication in the prior 3 months, we will assess severity.) Children not using a preventive medication at baseline: Assess for mild persistent to severe persistent asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine severity An average of >2 days per week with asthma symptoms >2 days per week with rescue medication use ≥2 nights per month awakened with nighttime symptoms Minor limitation of activity ≥2 episodes of asthma during the past year that have required systemic corticosteroids Children using a preventive medication at baseline: Assess for poorly controlled asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine control  Significant underlying respiratory disease other than asthma (such as cystic fibrosis or chronic lung disease) that could potentially interfere with asthma-related outcome measures Significant co-morbid conditions (such as moderate to severe developmental delay, i.e. special education classroom or diagnosis) that could preclude participation in an education-based intervention Inability to speak or understand English (child or parent) Children in foster care or other situations in which consent cannot be obtained from a guardian Prior enrollment in the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Severe Asthma Children with severe asthma Child aged 3 to 12 years Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene or short acting nebulized bronchodilators (inhaler technique and compliance verified) presents one of the following Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months exacerbations in the previous year at least one care unit admission or continued resuscitation at least two hospitalizations for acute severe asthma requiring IV therapy at least 2 courses of oral corticosteroids for exacerbations post BD FEV <80% or UARS post BD> 150% predicted Signature of consent or the holder (s) of parental authority  Child with bronchopulmonary dysplasia Child with severe sequelae of viral infections Refusal of the child or parents Data collection for research and follow up of patients : tests carried out in the 3 months prior to are used Blood sample for DNA extraction and the biobank: for young children, sampling at least 4 to 5 ml on dry tubes for serum and 6 ml at least for DNA. These samples should be stored at room temperature, transported within 48 hours to biological resources (CRB) Necker E,fa,ts Malades